医学
放射性核素治疗
肽受体
放射性核素
电流(流体)
肿瘤科
内科学
医学物理学
受体
量子力学
电气工程
物理
工程类
作者
David Bushnell,Kellie L. Bodeker
标识
DOI:10.1016/j.soc.2019.11.005
摘要
Peptide receptor radionuclide therapy (PRRT) is an effective form of treatment of patients with metastatic neuroendocrine tumors, delivering modest objective tumor response rates but notable survival and symptomatic benefits. The first PRRT approved by the US Food and Drug Administration was lutetium 177-DOTATATE and is for use in adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. The treatment paradigm typically leads to significant improvement in symptomology coupled with an extended period of progression-free survival. Side effects are limited, with a small fraction of individuals experiencing clinically significant long-term renal or hematologic toxicity.
科研通智能强力驱动
Strongly Powered by AbleSci AI